Position tracking has been widely used in medical applications, especially in 3D ultrasound imaging, where it has transformed the 2D slice limitation into 3D volume with bigger clinical impacts. As a game controller can also produce position tracking information, it has the potential to act as a low-cost and portable position tracker for ultrasound probes. This paper aims to investigate the feasibility of a game controller to perform as a position tracker and to design its implementation in 3D ultrasound imaging. The study consists of data acquisition and 3D ultrasound reconstruction for visualization. The data acquisition is accomplished by capturing the 2D ultrasound frame and its relative positional and orientation data by using an ultrasound probe and game controller respectively. These data are further reconstructed to produce 3D ultrasound volume for visualization. Our experiments include game controller position tracker testing and 3D ultrasound reconstruction on baby phantom. The results have confirmed that the game controller performance was closely aligned with that of in a robot arm. Also, the 3D ultrasound reconstruction implementation has revealed promising outcomes. With these features, the function of the currently available ultrasound probes can be prospectively improved using a game controller position tracker effectively. Graphical Abstract.
Erectile dysfunction is common in adult men, particularly those with hypertension and diabetes. The present study determines the effectiveness of angiotensin receptor blocker (ARB) drugs on erectile function in hypertensive male adults. For this purpose, CENTRAL and MEDLINE and reference lists of the articles were searched. The randomized controlled trials (RCTs) were selected that compared ARBs with conventional therapy or no treatment in men of any ethnicity who were presented with hypertension and/or diabetes. A total four trials that had 2,809 men were included. Three trials reported adequate random sequence allocation, two reported adequate blinding. Attrition bias is low in one of the included studies. All three studies are of low risk of selective reporting bias. There was an improvement in sexual activity with ARBs (valsartan) (mean difference (MD): 0.71, 95% Confidence Interval (CI) 0.66 to 0.76, I2 statistic = 0%). However, the erectile functions did not increase significantly in ARBs (losartan or telmisartan) treated men as compared to control or placebo (n = 203 vs n = 232; MD: 1.36; 95% CI: -0.97 to -3.69; I2 statistic = 80%). These results suggested that ARBs significantly improved sexual activity among hypertensive men. However, the erectile function was not significantly improved in ARBs treated men as compared to the control or placebo-treated. There were limited studies available. Hence, additional studies are needed to support findings from this review. ARBs should be considered when prescribing antihypertensive drugs to men.